CAR-DC
Phase 1Biologic
CAR-DC is one of 22 biologic programs targeting CAR. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in CAR
#DrugCompanyPhaseTrials
1Isopto Carpine
AAdvanz Pharma
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Floxin
WWim Janssens
Phase 3
Pelacarsen
NovartisPhase 3
L-Carnitine
IIperboreal Pharma Srl
Phase 3
Tegretol
NovartisPhase 1
Tylenol
KKenvue Brands
Phase 2
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Diamox
TevaPhase 1
Trileptal
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
CAR1 trial
CAR-DC for End-Stage IPF
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07329959·8 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CAR-DC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details